RS Research

Name: RS Research
Address: Teknopark Istanbul, Pendik, Istanbul, TR
Telephone: +905353408756

Home
Turkey
Istanbul
RS Research

Call Directions Website Contact the business

RS Research is a pharmaceutical company developing next generation of nanomedicines based on innovative drug delivery platform.

13/10/2026

Scientific progress grows through partnerships. Collaboration brings complementary capabilities and a broader perspective to innovators working on the same challenge.

We have been selected to join inaugural Startup Cohort at Global Health Exhibition 2026 in Riyadh, taking place on 26-29 October! As we prepare for our next stage of growth, we look forward to sharing our story on this distinguished platform.

Let's connect in Riyadh.

w/ Dr. Sena Nomak

25/09/2026

According to the International Pharmaceutical Federation (FIP), this year’s World Pharmacists Day theme is “Empowering pharmacists for healthier futures”. Today is about highlighting the skills, recognition and system support pharmacists need as health challenges evolve.

This message resonates with our work because every reliable step in drug development depends on careful formulation, responsible ex*****on and cross-disciplinary expertise. Cheers to the efforts of pharmacists who help turn scientific knowledge into trusted practice, from research environments to health systems.

w/ Prof. Rana Sanyal | Dr. Sena Nomak

14/09/2026

GITEX AI Türkiye brought together a remarkable mix of technology, investment and ecosystem perspectives. What made the two days especially valuable was the quality of the conversations.

Putting İstanbul on the map of a global platform such as GITEX sends a strong message about its growing place in the international innovation ecosystem.

Looking forward to unlocking the next chapter of dialogue together.

Invest in Türkiye | T.C. Sanayi ve Teknoloji Bakanlığı | GITEX Global

/w Prof. Rana Sanyal | Dr. Sena Nomak

04/09/2026

September is Gynecologic Cancer Awareness Month: a time to bring five distinct cancers, namely cervical, ovarian, uterine, vaginal and vulvar, into clearer view.

Their biology, treatment pathways and unmet needs are not identical. What unites them is the need for science that respects those differences and translates them into more precise options for patients.

For us, advancing innovation across solid tumors means building delivery approaches designed around where treatment needs to act, so powerful therapies can be explored with greater precision.

w/ Prof. Rana Sanyal | Dr. Sena Nomak

19/08/2026

We have been ranked 22nd in Fast Company Türkiye’s 2026 Startup 100, reflecting our growing recognition among prominent figures from Türkiye’s venture capital and finance community represented on this year’s jury. We are pleased to see our growth story gaining wider recognition.

This snapshot is an acknowledgement of not only our clinical progress and innovation, but also the strength of the scale-up model carrying that progress forward.

We look forward to giving our ecosystem many more milestones to celebrate with us!

w/ Prof. Rana Sanyal | Dr. Sena Nomak

15/08/2026

We are proud to receive the "Special Award for Game-Changing Technology", for our nanocarrier technology in cancer treatment, at Teknopark İstanbul's Vecihi Hürkuş Technology Awards.

The award recognizes innovation that creates strategic value and lasting impact, and it comes at a defining moment for us: RS-0139, Türkiye's first novel drug candidate, has successfully completed its Phase 1 clinical trial.

Türkiye's record in strategic industries shows what determined public support and a strong R&D ecosystem make possible. Biotechnology can be built on the same foundations, and we are working to open that path for those who follow.

Our sincere thanks to Teknopark İstanbul for standing beside RS Research since day one.

w/ Dr. Sena Nomak | Prof. Rana Sanyal

03/08/2026

Synthesis isn’t just about creating: it’s about transforming. Our experts blend science and technology to redefine what’s possible in treatment. Merging knowledge with innovation, we synthesize more than just new compounds; we’re creating a future where traditional limits no longer apply.

Synthesis is where our passion meets progress, turning simple chemicals into ground-breaking therapies that challenge the contemporary boundaries. Our synthesis processes represent the very core of innovation in nanomedicine.

With our team’s unique , we transform our extraordinary clinically-validated nano carriers into powerful treatments to disrupt the efficacy-toxicity trade-off.

*“ ” reflects RS Research’s way of defining a series of key concepts, and our success stems from this difference in perception.

w/ Prof. Rana Sanyal | Dr. Sena Nomak

17/07/2026

We’re proud to share that our Phase 1 study of RS-0139 is now part of the Congress 2026 scientific programme: “First-in-human phase Ia/Ib study of RS-0139, an integrin-targeted docetaxel prodrug, in advanced solid tumors”

This will mark the first detailed public disclosure of our completed Phase 1 study and represents an important milestone in the clinical validation of our Sagitta® platform. Our Medical Director, Gulsah Nomak, MD, will represent our team as the global oncology community gathers in Madrid to shape what comes next in targeted therapies.

We look forward to sharing the full results from our lead investigational drug at ESMO - European Society for Medical Oncology Congress 2026.

w/ Prof. Rana Sanyal | Dr. Sena Nomak

01/07/2026

Small technical decisions define the speed and quality of translation.

Building GMP-certified manufacturing capability in-house was a strategic development choice for us: to keep formulation know-how, process understanding, analytical control and clinical supply planning close to the science.

At this inflection point, that capability allows our teams to move faster between design and clinical decisions, while reducing avoidable dependency in critical development steps. It translates to a clearer path from platform idea to investigational product.

At the doorstep of our broader development, including RS-0139’s Phase 2 clinical trial preparation, GMP capability is not just something we have built. It is part of our scale-up journey.

w/ Prof. Rana Sanyal | Dr. Sena Nomak

24/06/2026

Translation isn’t just about languages: for us it’s about turning discovery into impact. We specialize in the translation of lab insights into real-world therapies that transform patient care.

We bridge the gap between molecules and medicine; between research and reality. Our journey is one of adaptation, precision and purpose, making science speak the language of healing.

Our peRSpective*: science should not stay on the shelf. It must reach the bedside.

*“ ” reflects RS Research’s way of defining a series of key concepts, and our success stems from this difference in perception.

w/ Prof. Rana Sanyal | Dr. Sena Nomak

Address

Teknopark Istanbul, Pendik
Istanbul

Telephone

+905353408756

Website

http://www.rsresearch.net/

Alerts

Be the first to know and let us send you an email when RS Research posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to RS Research:

Want your business to be the top-listed business in Istanbul?